

STRUCTURAL CHARACTERIZATION AND INTERACTION STUDIES OF HUMAN LIPOCALIN-TYPE PROSTAGLANDIN D SYNTHASE (L-PGDS)

M. Perduca, M. Bovi, S. Capaldi and H.L. Monaco

Biocrystallography Laboratory, University of Verona, Italy.

Lipocalin-type prostaglandin D synthase (L-PGDS) catalyzes the isomerisation of the 9,11-endoperoxide group of PGH₂ (Prostaglandin H₂) to produce PGD₂ (Prostaglandin D₂) with 9-hydroxy and 11-keto groups in the presence of sulphhydryl compounds. PGH₂ is a common precursor of all prostanoids, which include thromboxanes, prostacyclins and prostaglandins. PGD₂ is synthesized in both the central and peripheral nervous system and it is involved in many regulatory events. L-PGDS, the first member of the important lipocalin family to be recognized as an enzyme, is also able to bind and transport small hydrophobic molecules and was formerly known as β -trace protein, the second most abundant protein in human cerebro-spinal fluid. L-PGDS is also detected in brain, testis and prostate, endothelial cells, placenta and heart tissue and even in macrophages infiltrated in atherosclerotic plaques. In these tissues it participates in many physiological activities as well as in the response to diseases. In this work we use recombinant human L-PGDS in order to solve its three-dimensional structure by X-ray diffraction and test its affinity for several ligands using Surface Plasmon Resonance (SPR). Wild type human L-PGDS and three mutants (C65A; C65A-K59A; C89/186A) were expressed using E. coli cell strains and subsequently purified by a chitin affinity column, size exclusion and hydrophobic interaction chromatography. Large and highly ordered crystals were used to collect X-ray diffraction data using either a rotating-anode generator or a synchrotron source. The multiple isomorphous replacement method was used to solve the phase problem. In the electron density maps an unidentified density was observed apparently interacting with lysine 59 inside the L-PGDS-C65A cavity; the foreign molecule could be PEG, an additive present in the crystallization liquors. This hypothesis is supported by the fact that the L-PGDS-C65A/K59A crystals, which grow without PEG, show a completely free protein cavity. A seeding experiment of L-PGDS-C65A/K59A crystal, grown in L-PGDS-C65A crystallization conditions, partially confirmed this hypothesis since the foreign molecule was present in the L-PGDS-C65A/K59A cavity. Another molecule that can explain this foreign density is triacontyl acetate, that can be present in the Luria Bertani medium used to growth E. coli cells. We are currently trying to establish the identity of the unknown ligand. Another crystal form was obtained by mixing L-PGDS-C65A/K59A with the amyloid β peptide (1-40). Although the amyloid β peptide is not visible in the maps, the packing of the protein molecules was changed in the presence of the peptide suggesting interaction of the two molecules. Wild type L-PGDS small crystals were recently obtained and will be tested as soon as synchrotron beam time becomes available.